Johnson & Johnson Proposes $5.5 Billion Talc Settlement to Resolve U.S. Ovarian Cancer Lawsuits 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Zhongji Innolight Raises $6.8 Billion in Hong Kong IPO as AI Demand Fuels Growth 
TeamViewer Shares Fall Despite Profit Growth as ARR and Customer Base Decline 
Sika Raises 2026 Sales Outlook After Strong First-Half Results Beat Expectations 
BHP, Port Hedland Unions Fail to Reach Wage Deal as Negotiations Continue 
Galp Shares Fall After Q2 EBITDA Miss Despite Profit Beat and Higher Dividend 
Meta CEO Zuckerberg Opposes U.S. Ban on Chinese AI Models, Warns Against Overregulation 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Exosens H1 Profit Beats Forecasts as Defense Demand Drives Growth 
Seagate Stock Jumps as AI-Fueled Earnings Beat and Strong FY2027 Outlook Impress Investors 
Unilever Raises 2026 Sales Outlook After Strong Q2 Volume Growth 
SK Hynix Q2 Profit Hits Record as AI Memory Chip Demand Fuels Growth 
ASML, Applied Materials Slide as China DUV Chip Equipment Breakthrough Sparks Market Jitters 
Hanmi Pharmaceutical will get US$10 million from Merck Sharp & Dohme (MSD) as initial contract payment in an $860 million exclusive licensing deal for the development, manufacture, and commercialization of its liver treatment candidate material efinopegdutide.
Under the deal, Hamni will be getting royalty payments from MSD with the development of the efinopegdutide.
However, the overall payment MSD will give Hanmi is contingent on regulatory permission and the drug's success in the market.
Efinopegdutide is for treating nonalcoholic steatohepatitis (NASH), a condition where the liver suffers inflammation and damage due to excess fat in the organ.
The South Korean pharmaceutical firm claimed findings from the latest phase 2 studies have provided compelling clinical evidence that the material can be used on people with NASH.
Efinopegdutide was originally developed for insulin secretion and obesity control, in cooperation with Janssen Pharmaceutica.
A 2015 deal to develop and market the drug through due to shortfalls related to blood sugar level control.
